A5037336563- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Signaling Pathways in Disease
- Neuroendocrine Tumor Research Advances
- PARP inhibition in cancer therapy
- Chronic Lymphocytic Leukemia Research
- Bladder and Urothelial Cancer Treatments
- Cancer Genomics and Diagnostics
- Occupational and environmental lung diseases
- Economic and Financial Impacts of Cancer
- Radiomics and Machine Learning in Medical Imaging
- Pleural and Pulmonary Diseases
- Urinary and Genital Oncology Studies
- Lymphoma Diagnosis and Treatment
Istituti di Ricovero e Cura a Carattere Scientifico
2023-2024
University of Padua
2019-2024
Istituto Oncologico Veneto
2023-2024
Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients at least three metastatic sites, brain metastases, and symptoms diagnosis seem to have worse prognosis.Osimertinib became the standard treatment for untreated cancer (aNSCLC) following results reported phase...
ctDNA is a useful tool for NGS molecular profiling in advanced NSCLC patients. Its clinical applicability patients with gene rearrangements still limited due to lower detection rate of these types alterations compared single SNVs or small indels. To this purpose, we performed study two Italian centers assess the concordance between tissue and plasma samples genes fusions (ALK, ROS, RET) METexon14 mutations Patients histological diagnosis oncogene addicted ROS1, RET positive mutated) were...
The observational multicenter prospective FLOWER study (NCT04965701) confirmed effectiveness and safety of osimertinib in the real-world (RW) management untreated EGFR-mutant advanced non-small cell lung cancer (aNSCLC) patients.
Rearranged during transfection (RET) gene rearrangements occur in 1%-2% of non-small cell lung cancer (NSCLC). Because the results study LIBRETTO-001, selpercatinib has been approved as first-line treatment for patients with RET fusion-positive advanced NSCLC. Selpercatinib demonstrated to be well tolerated. Despite this, gastrointestinal adverse events (AEs) are frequently reported, and no clinical-radiological endoscopic features their impact terms discontinuations, interruptions, dose...
Aims: This study describes real-world outcomes of pretreated EGFR T790M-positive (T790M+) advanced non-small-cell lung cancer patients progressing after first- or second-generation tyrosine kinase inhibitors and receiving osimertinib, compared with T790M-negative (T790M-) patients. We have also described progression patterns treatment sequences. Patients & methods: is a retrospective multicenter Italian observational including consecutive Caucasian referred between 2014 2018. Results: 167...
The difference in circulating cytokines levels between epithelioid (E) or non-epithelioid (NE) Pleural Mesothelioma (PM) and their modulation after chemotherapy (ChT) immune checkpoint inhibitors (ICIs) have not yet been described. This prospective translational study included patients (pts) with E NE PM treated respectively ChT ICIs. primary aim was to explore the prognostic role of levels, dynamic change during ICIs correlation progression-free survival (PFS). Blood samples were collected...
e20612 Background: Acquired T790M EGFR mutation (mut) is not predictable by any clinical-pathological feature. The best time point for mut detection liquid or tissue biopsy currently undefined. Methods: This an observational study at 6 Italian Centers enrolling mutant NSCLC patients (pts) progressing after first/second generation TKI, between 2014 and 2018. primary endpoint of the was to compare clinical features in acquired T790M+ compared with T790M- cases. secondary assess different...